Second Genome, Pfizer to Conduct Microbiome Research | GenomeWeb

NEW YORK (GenomeWeb) – Second Genome today announced a deal with Pfizer to conduct a large microbiome observational study to find out more about obesity and metabolic diseases.

The study is aimed at evaluating clinical factors and the microbiome in a cohort of about 900 individuals with various metabolic phenotypes in order to elucidate the interrelationship between the microbiome, obesity, and metabolic disorders, Second Genome said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.